Latest News – Page 57 – The Market Genie

US stocks are also set to rise when markets open later on. Futures for the Dow ( YM=F) were 0.6% higher, while the S&P

Compass Point Analyst Sings the Praises of These 2 Financial Stocks

November 25, 2024November 25, 2024

As we face the likelihood of significant shifts in economic policy under incoming President Trump, it’s time to start taking a closer look at

These Stocks Are Moving the Most Today: Super Micro, Snowflake, Palantir, MicroStrategy, Robinhood, Macy’s, and More

November 25, 2024November 25, 2024

Posted By: techrossm

Shares of Super Micro Computer extend last week’s sharp gains, Snowflake stock is upgraded, and MicroStrategy may soon unveil a fresh purchase of Bitcoin.

How mutual funds performed on risk adjusted returns?

November 25, 2024November 25, 2024

Posted By: techrossm

How mutual funds performed on risk adjusted returns?

Edelweiss shares rise 3% amid buzz of firm hiring Nomura for mutual fund unit stake sale

November 25, 2024November 25, 2024

Posted By: techrossm

Shares of Mumbai-based Edelweiss Financial Services Ltd rose over 3% on November 25 after a report said the financial services group is likely to

Edelweiss stake sale: Company to sell up to 35% stakes in Mutual Fund business

November 25, 2024November 25, 2024

Posted By: techrossm

Edelweiss Financial Services is exploring a sale of a 25% to 35% stake in its Mutual Fund unit, a Bloomberg report said. The financial

Foreign investors turn net buyers of Indian stocks after record selling run

November 25, 2024November 25, 2024

Posted By: techrossm

Foreign institutional investors turned net buyers of Indian equities on Monday, provisional exchange data showed, snapping a record selling streak that had partly caused

The abolitionist legacy and the future of impact investing

November 25, 2024November 25, 2024

Posted By: techrossm

“Oikos has established a loan fund to help churches and community organizations access the capital necessary for their initiatives.” …

Investing in the Community

November 25, 2024November 25, 2024

Posted By: techrossm

For nearly 150 years, Eli Lilly and Company has discovered and developed innovative, lifesaving, life-changing medicines for people with chronic illnesses such as diabetes,

YYY: A Cautionary Tale Of High-Fee, Low-Return Investing

November 25, 2024November 25, 2024

Posted By: techrossm

Amplify High Income has a poor historical performance and the fund charges a high expense ratio for the management of the fund. Learn more

themarketgenie.net is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of themarketgenie.net are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.

The sender of this email makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.

The content on any of themarketgenie.net websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options.

The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.

Disclaimer: Past performance is no guarantee of future performance. This product is for educational purposes only. Practical application of the products herein are at your own risk and themarketgenie.net, its partners, representatives and employees assume no responsibility or liability for any use or mis-use of the product. Please contact your financial advisor for specific financial advice tailored to your personal circumstances. Any trades shown are hypothetical example and do not represent actual trades. Actual results may differ. Nothing here in constitutes a recommendation respecting the particular security illustrated.